Evidence map›Paper›PMID 38178674›Full record

ArticleCurrent cancer drug targets2024

CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells.

Kelly C Arias Cardenas, Clinton W Enos, Mark R Spear, Dana E Austin, Raghad Almofeez, Stephanie Kortchak, Lauren Pincus, Hua-Bei Guo, Samuel Dolezal, J Michael Pierce and 4 more

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in Current cancer drug targets, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Exploring the interactions of integrins and CEACAM6 (Review).Experimental and therapeutic medicine · 2025
    Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Kelly C Arias CardenasStromatis Pharma, 9501 Discovery Blvd Manassas, VA 20109, USA.
Clinton W EnosEastern Virginia Medical School, Norfolk, Virginia, USA.
Mark R SpearStromatis Pharma, 9501 Discovery Blvd Manassas, VA 20109, USA.ORCID 0000-0001-8722-643X
Dana E AustinStromatis Pharma, 9501 Discovery Blvd Manassas, VA 20109, USA.ORCID 0000-0001-6527-2961
Raghad AlmofeezStromatis Pharma, 9501 Discovery Blvd Manassas, VA 20109, USA.
Stephanie KortchakStromatis Pharma, 9501 Discovery Blvd Manassas, VA 20109, USA.
Lauren PincusStromatis Pharma, 9501 Discovery Blvd Manassas, VA 20109, USA.
Hua-Bei GuoUniversity of Georgia Cancer Center, Department of Biochemistry and Molecular Biology and the Complex Carbohydrate Research Center (CCRC), USA.
Samuel DolezalUniversity of Georgia Cancer Center, Department of Biochemistry and Molecular Biology and the Complex Carbohydrate Research Center (CCRC), USA.
J Michael PierceUniversity of Georgia Cancer Center, Department of Biochemistry and Molecular Biology and the Complex Carbohydrate Research Center (CCRC), USA.
Emma FurthPerelman School of Medicine at the University of Pennsylvania, Philadelphia, USA.
Cyrille GinesteVaxxinity Inc, Merritt Island, Fl, USA.
Yongjun KwonInstitute: Food and Drug Administration, CDER, MD, USA.
Cohava GelberStromatis Pharma, 9501 Discovery Blvd Manassas, VA 20109, USA.ORCID 0000-0002-3894-5021
Tris Pharma (United States) · USUniversity of Georgia · USEastern Virginia Medical School · USMerritt College · USUnited States Food and Drug Administration · USUniversity of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCEACAM5 and CEACAM6 are glycosylphosphatidylinositol (GPI)- linked members of the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family, which are frequently upregulated in epithelial cancers where they contribute to invasion, metastasis, immune evasion, and resistance to anoikis. CT109 is a novel antibody with dual specificity to both CEACAM5 and 6.

objectivesIn this study, we aimed to perform the preclinical characterization of CT109 and antibody- drug conjugate (ADCs) derivatives of CT109, focusing on CT109-SN-38.

methodsCT109's cognate epitope was characterized by scanning mutagenesis. CT109 specificity and internalization kinetics were assessed by immunoblot and flow cytometry, respectively. Cognate antigen expression prevalence in colorectal cancer and normal tissue arrays was determined by immunohistochemistry. CT109 conjugations were generated by the reaction of reduced CT109 cysteines with maleimide-functionalized payload linkers.

resultsCT109 was shown to bind a glycoepitope centered on N309. CT109 is internalized in the CEACAM5

conclusionThese data suggest that further preclinical and clinical development of CT109-SN-38 is warranted.

Indexed as

Carcinoembryonic AntigenCell Adhesion MoleculesGPI-Linked ProteinsPancreatic NeoplasmsAnimalsAntigens, CDCell Line, TumorFemaleHumansImmunoconjugatesIrinotecanMiceMice, NudeXenograft Model Antitumor AssaysAntigens, CDCarcinoembryonic AntigenCEACAM5 protein, humanCEACAM6 protein, humanCell Adhesion MoleculesGPI-Linked ProteinsImmunoconjugatesIrinotecanADCantibody-drug conjugateCEACAM5CEACAM6pancreatic ductal adenocarcinomaSN-38.

Identifiers

PMID38178674
OpenAlexW4390612337

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.